menu

Connecting Care: Outpatient Treatment of COVID-19 With Neutralizing Monoclonal Antibodies

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Connecting Care: Outpatient Treatment of COVID-19 With Neutralizing Monoclonal Antibodies

close
0.75 credits
30 minutes

CME/CE Broadcast Replay

Connecting Care: Outpatient Treatment of COVID-19 With Neutralizing Monoclonal Antibodies
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.75 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    The United States is one of the hardest hit countries with SARS-CoV-2 with many more deaths expected in early 2021. Outpatient infusion treatment with neutralizing monoclonal antibodies (nAbs) is an important treatment option for some patients. This 30-minute ReachMD program helps you recognize appropriate patients for nAb-therapy and presents the most recent evidence on ambulatory options. Get expert perspectives from a physician and pharmacist as they present compelling case studies. This broadcast replay includes a pre-read summarizing key clinical trial information.

  • Disclosure of Conflicts of Interest

    Disclosure and Conflict of Interest Resolution
    Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s).* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity. 
    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity: 

    • Planners (Forefront Collaborative):  Leah Johnson, and Marianna Shershneva, MD, PhD
    • Planner (Medical Writer): Debra Gordon
    • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, Bernadette Marie Makar, MSN, APRN, BC, NP-C, and Dorothy Duffy, BS Pharmacy
    • Faculty: Jennifer Caudle, MD and Chad Worz, PharmD, BCGP, FASCP

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:  
    Faculty: Andrew Badley, MD, FRCP(C), FACP, FIDSA

    • Advisory Board: AbbVie, Flambeau Diagnostics
    • Ownership Interest (Excluding Diversified Mutual Funds): nference, Splissen Therapeutics, Zentalis
    • Other: Data Safety and Monitoring Board—Corvus, Equillium

    Planner (Forefront Collaborative): Lilia Zurkovsky, PhD  

    • Stock Ownership: Teva 

    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    This activity is designed for physicians, nurse practitioners (NPs), physician assistants (PAs), nurses, pharmacists, and paramedics practicing in the US and involved in the outpatient care and treatment of patients with COVID-19.

  • Learning Objectives

    As a result of participation in the proposed educational initiative, participants should be able to

    1. Recognize risk factors that may increase the likelihood of patients with COVID-19 developing severe illness.
    2. Discuss the most recent evidence regarding the use of outpatient therapies to reduce the risk of progression in patients with COVID-19.
    3. Describe the requirements for the outpatient delivery of virus-neutralizing monoclonal antibodies (nAbs) to patients with COVID-19.
    4. Collaborate with ambulatory infusion services for the outpatient care of patients with COVID-19.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    Credit Designation Statement
    Forefront Collaborative designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CME Content Review
    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.
    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

     In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Nurses
    Credit being awarded: 0.75 ANCC contact hours 

    Nurse Practitioners

    This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803

    This enduring activity is approved for 0.75 contact hour(s) which includes 0.75 hour(s) of pharmacology. Activity ID #20235-1E

    This activity was planned in accordance with AANP Accreditation Standards and Policies.

    Pharmacists
    0.75 contact hours

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative and AKH Inc.. 

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The United States is one of the hardest hit countries with SARS-CoV-2 with many more deaths expected in early 2021. Outpatient infusion treatment with neutralizing monoclonal antibodies (nAbs) is an important treatment option for some patients. This 30-minute ReachMD program helps you recognize appropriate patients for nAb-therapy and presents the most recent evidence on ambulatory options. Get expert perspectives from a physician and pharmacist as they present compelling case studies. This broadcast replay includes a pre-read summarizing key clinical trial information.

  • Disclosure of Conflicts of Interest

    Disclosure and Conflict of Interest Resolution
    Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s).* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity. 
    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity: 

    • Planners (Forefront Collaborative):  Leah Johnson, and Marianna Shershneva, MD, PhD
    • Planner (Medical Writer): Debra Gordon
    • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, Bernadette Marie Makar, MSN, APRN, BC, NP-C, and Dorothy Duffy, BS Pharmacy
    • Faculty: Jennifer Caudle, MD and Chad Worz, PharmD, BCGP, FASCP

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:  
    Faculty: Andrew Badley, MD, FRCP(C), FACP, FIDSA

    • Advisory Board: AbbVie, Flambeau Diagnostics
    • Ownership Interest (Excluding Diversified Mutual Funds): nference, Splissen Therapeutics, Zentalis
    • Other: Data Safety and Monitoring Board—Corvus, Equillium

    Planner (Forefront Collaborative): Lilia Zurkovsky, PhD  

    • Stock Ownership: Teva 

    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    This activity is designed for physicians, nurse practitioners (NPs), physician assistants (PAs), nurses, pharmacists, and paramedics practicing in the US and involved in the outpatient care and treatment of patients with COVID-19.

  • Learning Objectives

    As a result of participation in the proposed educational initiative, participants should be able to

    1. Recognize risk factors that may increase the likelihood of patients with COVID-19 developing severe illness.
    2. Discuss the most recent evidence regarding the use of outpatient therapies to reduce the risk of progression in patients with COVID-19.
    3. Describe the requirements for the outpatient delivery of virus-neutralizing monoclonal antibodies (nAbs) to patients with COVID-19.
    4. Collaborate with ambulatory infusion services for the outpatient care of patients with COVID-19.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    Credit Designation Statement
    Forefront Collaborative designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CME Content Review
    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.
    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

     In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Nurses
    Credit being awarded: 0.75 ANCC contact hours 

    Nurse Practitioners

    This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803

    This enduring activity is approved for 0.75 contact hour(s) which includes 0.75 hour(s) of pharmacology. Activity ID #20235-1E

    This activity was planned in accordance with AANP Accreditation Standards and Policies.

    Pharmacists
    0.75 contact hours

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative and AKH Inc.. 

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/5/21